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Background: Iron binding, naturally occurring protein bovine lactoferrin (bLf) has attracted attention as a safe
anti-cancer agent capable of inducing apoptosis. Naturally, bLf exists partially saturated (15-20%) with Fe3+ however, it
has been demonstrated that manipulating the saturation state can enhance bLf’s anti-cancer activities.
Methods: Apo-bLf (Fe3+ free) and Fe-bLf (>90% Fe3+ Saturated) were therefore, tested in MDA-MB-231 and MCF-7
human breast cancer cells in terms of cytotoxicity, proliferation, migration and invasion. Annexin-V Fluos staining was
also employed in addition to apoptotic protein arrays and Western blotting to determine the specific mechanism of
bLf-induced apoptosis with a key focus on p53 and inhibitor of apoptosis proteins (IAP), specifically survivin.
Results: Apo-bLf induced significantly greater cytotoxicity and reduction in cell proliferation in both cancer cells
showing a time and dose dependent effect. Importantly, no cytotoxicity was detected in normal MCF-10-2A cells. Both
forms of bLf significantly reduced cell invasion in cancer cells. Key apoptotic molecules including p53, Bcl-2 family
proteins, IAP members and their inhibitors were significantly modulated by both forms of bLf, though differentially in
each cell line. Most interestingly, both Apo-bLf and Fe-bLf completely inhibited the expression of survivin protein
(key IAP), after 48 h at 30 and 40 nM in cancer cells.
Conclusions: The capacity of these forms of bLf to target survivin expression and modulation of apoptosis demonstrates
an exciting potential for bLf as an anti-cancer therapeutic in the existing void of survivin inhibitors, with a lack of
successful inhibitors in the clinical management of cancer.
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Apoptosis is a key target for anti-cancer therapy given
that it is commonly disrupted in tumourigenesis, allow-
ing diseased cancerous cells to remain and proliferate
within the body. Inhibitor of apoptosis proteins (IAPs),
play a key role in the ability of cancer to avoid apoptotic
signals. Survivin is a 16 kDa protein of the IAP family
that enhances cell survival and is over expressed in many
cancer cells [1]. Due to its overexpression in cancer, survi-
vin is a key target for cancer therapy. Survivin inhibits
apoptosis by directly binding to pro-apoptotic molecules,
including caspase family proteins, allowing the progression* Correspondence: rupinder.kanwar@deakin.edu.au
Nanomedicine - Laboratory for Immunology and Molecular Biomedical
Research, Molecular and Medical Research Facility, School of Medicine, Faculty
of Health, Deakin University, Geelong, Victoria, Australia
© 2015 Gibbons et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.of cell growth and survival [1–3]. The caspase family
consists of initiator caspases-8 and −9 of the extrinsic and
intrinsic pathways respectively, as well as executioner
caspases-3 and −7.
Lactoferrin (Lf ) is a naturally occurring, ferric (Fe3+)
iron binding glycoprotein [4]. Naturally, Lf has antibac-
terial and antimicrobial properties and is present in exter-
nal mammalian excretions including tears, sweat and most
importantly milk [4–6]. Bovine lactoferrin (bLf) has been
associated with immune boosting and anti-carcinogenic
properties [7]. Purified bLf has been shown to increase
interferon-γ (IFN-γ), caspase-1 and interleukin-18 (IL-18)
[5, 8] as well as increasing the levels of immune cells in
various mice models [5, 8, 9]. BLf is approved by the
Therapeutic Goods Administration (Australia), Food and
Drug Administration (USA) and the European Food Safetyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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products [10–12].
Native bLf (15-20% iron saturated) has been shown to
inhibit growth of colon, lung, bladder, squamous and
mammary gland tumour cells [13–19] and had been re-
ported to induce apoptosis in colon, lung, stomach and
breast cancers [6, 20]. Specifically, apoptosis was reported
in two breast cancer cells lines T47D and HS578D with
native bLf at concentrations of 0.125-125 μM along with a
reduction in cell migration [21]. Activation of apoptosis by
bLf has been reported via the modulation of both the ex-
trinsic and intrinsic pathways. BLf has been reported to
up-regulate the sensitivity of extrinsic pathway death re-
ceptor Fas as well as inducing caspase-3 and −8 cleavage
in colon cancer models [22, 23] Results from the same
studies also indicated up-regulation of pro-apoptotic Bcl-2
family genes Bax and Bid. Studies have also reported that
native bLf significantly decreased the levels of intrinsic
anti-apoptotic protein Bcl-2 in stomach cancer cells [20].
Whilst native bLf is approximately 15-20% saturated, it
can be modified to forms with different levels of iron:
Apo-bLf (<5% iron saturation) and Holo-bLf (100% iron
saturated) [4, 24]. In comparison to Apo-bLf, iron satu-
rated bLf is more resistant to in vivo gut digestion [25,
26]. The concept that bLf iron saturation levels can
affect its anti-tumour activity was not tested until 2008,
when we reported that iron saturated (>98%) Fe-bLf,
when fed orally to mice, displays anti-tumour properties,
increasing apoptosis and cytotoxicity as well as targeting
angiogenesis [24]. Importantly, Fe-bLf has been shown
to restore red and white bloods cells following chemo-
therapy [24] and increase the sensitivity of tumours to
chemotherapeutic drugs [25, 27]. Fe-bLf encapsulated in
ceramic nanocarriers has also proved very effective.
When fed orally, we observed a complete inhibition of
tumourigenesis in colon cancer xenograft mice in both
prevention and treatment models with tumour rejection
and regression respectively [25]. In addition, iron-free
(Apo-bLf ) and selenium saturated bLf (Se-bLf) have
shown anti-oxidant effects in colon cancer cells [28, 29].
BLf has a proven high safety profile reported widely by
pre-clinical animal studies and human clinical trials [6,
25, 30, 31]. Apo-bLf is thought to have enhanced anti-
cancer properties through its capacity to bind free Fe3+,
acting as an iron chelating agent [32–36]. This could be
of particular importance in breast cancer in relation to
iron metabolism [37]. Abnormalities in iron metabolism
have been associated with chemoresistance in breast
cancer cells [38]. As iron is essential for many cellular
processes and with a rapid growth rate, high iron levels
are essential in the tumour microenvironment [39, 40]
allowing for cell growth, proliferation and angiogenesis.
Thus chelating agents that can inhibit these processes
have great potential.While apoptosis has been observed in many cancer
cell types with native bLf, the specific mechanism of
apoptosis in breast cancer cells following Apo-bLf and
Fe-bLf treatment remains unclear; we hypothesised that
apoptosis would also be initiated in two breast cancer
cells MDA-MB-231 and MCF-7 with Apo-bLf and Fe-
bLf. It was hypothesised that these two bLf forms would
differentially (due to differences in iron level) modulate
the apoptosis, and molecules from each of the IAP and
caspase families. The effects of both Apo-bLf and Fe-bLf
in MDA-MB-231 and MCF-7 human breast adenocar-
cinoma cell lines were therefore investigated. Both forms
of bLf were also tested on non-tumourigenic mammary
epithelial cell line, MCF-10-2A. Furthermore, tumouri-
genic properties such as migration and invasion were
also studied in breast cancer cells. Full investigation into
the mechanisms and pathways activated in terms of




MDA-MB-231, MCF-7 and MCF-10-2A cell lines were
obtained from the American Type Culture Collection
(ATCC). MDA-MB-231 were maintained in Leibovitz’s
L15 medium (Life Technologies) supplemented with 10%
FBS and antibiotic-antimytotic. MCF-7 cells were main-
tained in Eagle’s Minimum Essential Medium (EMEM, Life
Technologies) supplemented with 10% FBS, antibiotic-
antimytotic and 0.01 mg/ml bovine insulin (Life Technolo-
gies). MCF-10-2A cells were maintained in Dulbeccos
modified Eagle medium (DMEM)/Ham’s F12 medium (Life
Technologies) with 10% horse serum, 0.01 mg/ml bovine
insulin, 20 ng/ml epidermal growth factor, 100 ng/ml Chol-
era toxin, 500 ng/ml hydrocortisone and antibiotic-
antimytotic. Cells were incubated at 37 °C, MCF-7 and
MCF-10-2A cells in the presence of 5% CO2.
Lactoferrin preparation
Apo-bLf (iron free) was prepared from commercial
grade pure, endotoxin (LPS) free, native bLf. Briefly,
80 mg/ml native bLf was dissolved in Milli-Q water and
iron released by reducing pH to 2.06. The bLf solution
was then dialysed in 50 kDa molecular weight cut-off
dialysis tubing against 0.1 M citric acid for 48 h and pH
adjusted back to 8.0. Fe-bLf (iron-saturated) was pre-
pared by the addition of ferric nitriloacetate (Fe-NTA) to
Apo-bLf drop wise until the solution reached a deep red
colour indication iron saturation. The Fe-bLf solution
was then dialysed against Milli-Q water for 48 h. Pro-
tein estimation was performed using the Coomassie
Plus (Bradford) Protein Assay (Thermo Scientific) and
purification was confirmed via SDS-PAGE (results not
shown).
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Cell cytotoxicity was determined using a cytotoxicity de-
tection, lactate dehydrogenase release (LDH) assay kit
(Roche). Cells were grown in 96-well plates (2 × 105
cells/ml, 200 μl/well) for 48 h prior to 24 and 48 h treat-
ment with 5, 10, 20, 30 and 40 nM Apo-bLf and Fe-bLf.
Supernatants from cells were incubated with LDH reac-
tion mixture and incubated for 30 min in fresh micro-
plates. Plates were then read at a wavelength of 492 nm
with a reference of 620 nm. High (100% cytotoxicity)
and low (0% cytotoxicity) controls were used to calculate
relative percentages of each treatment group.
CyQUANT® assay
The CyQUANT® cell proliferation assay (Life Technolo-
gies) was performed on both MDA-MB-231 and MCF-7
treated cells as per manufacturer’s instructions. Briefly,
cells were plated in 96-well plates, treated with both Apo-
bLf and Fe-bLf for 24 and 48 h at concentrations of 20, 30
and 40 nM. Treatment media was then removed and mir-
coplates were frozen at −80 °C overnight. Plates were then
thawed and cells were incubated with CyQUANT® GR
dye/cell lysis buffer prepared as per kit instructions. Plates
were then read at 480 nm excitation and 520 nm emission
maxima using a fluorescent spectrophotometer.
Immunofluorescence
Immunofluorescence was performed on both cancer cells
for bLf to determine the localisation of bLf into the cells.
Cells were seeded onto 8-chamber well slides and let to
grow until 70% confluent. Cells were then treated with ei-
ther form of bLf at 40 nM for 4 h. Cells were then fixed in
4% paraformaldehyde and blocked in 2% BSA followed by
incubation in anti-bovine lactoferrin primary antibody
(Bethyl Laboratories) and Alexa-Fluor 594 conjugated
anti-goat secondary antibody (Life Technologies) for
1 h each. Cells were then washed in phosphate buff-
ered saline (PBS) before chamber removal and mounting
media containing DAPI application. Slides were then cov-
ered, sealed and imaged via confocal microscope and soft-
ware (Leica TCS SP5).
Migration/Invasion assay
Both migration and invasion assays were performed in
24 well plates with 8 μm pore membrane, ThinCert™ cell
culture inserts (Greiner). Briefly, plates were set up with
media containing 10% FBS in the lower compartment.
Inserts were then placed into wells and 200 μl of 1% FBS
media containing 2 × 104 cells was seeded into each in-
sert. To this, treatments of 5 or 10 nM Apo-bLf or Fe-
bLf were added and total system was incubated for 24 h.
After which, ThinCertTM chambers were removed and
membranes fixed in 4% paraformaldehyde. Cells were
stinaed with 0.2% crystal violet and cells on the bottom(i.e. those that had migrated through the membrane)
were counted (5 representative fields) and averaged. In-
vasion assays were performed in the same way however
an artificial extracellular matrix (ECM) was placed on
the membrane prior to cell seeding to test invasive prop-
erties. MaxGel™ ECM (Sigma-Aldrich) was used accord-
ing to manufacturer’s instructions. Both invasion and
migration were represented as a percentage of control
(untreated) cell counts.
Annexin-V-fluos apoptosis assay
Apoptosis was detected via an Annexin-V-Fluos staining
kit (Roche) according to manufacturer’s protocol. MDA-
MB-231 and MCF-7 cells grown in 12 well plates were
treated with either Apo-bLf or Fe-bLf at 20 or 40 nM
for 24 h. Following treatment, cells were trypsinised and
pelleted, washed in PBS and again pelleted. Cells were
resuspended in Annexin-V-Fluos labelling solution con-
sisting of Annexin-V-Fluorescein labelling reagent and
propidium iodide (PI). Cells were incubated in the label-
ling solution for 20 min at room temperature before
analysis via flow cytometry (BD Biosciences). Cells were
gated according to PI and Annexin-V staining. Cells
positive for Annexin-V only were considered early apop-
totic, cells positive for PI only were considered necrotic
and cells double positive were taken as late apoptotic/
dead. Assays were performed in duplicate.
Apoptotic array
Human apoptosis protein arrays (R&D Systems) were
employed to screen 35 pro and anti-apoptotic molecules
from both the extrinsic and intrinsic pathways. Capture
and control antibodies were spotted in duplicate onto
nitrocellulose membranes which were subsequently in-
cubated with 250 μg whole cell lysate overnight. Follow-
ing incubation with kit buffers and reagents, membranes
were viewed using chemiluminescence detection and
spot densities analysed via Image J (National Institutes
of Health).
Western blotting
Western Blotting was performed with cell lysates pre-
pared from cells treated for 48 h in either Apo or Fe-bLf
at concentrations of 20, 30 and 40 nM as well as from
untreated cells. After treatments, cells were washed in
sterile PBS and lysed in RIPA buffer (0.6057 g Tris base,
0.877 g NaCl, 10 ml Nonident P‐40, 5 ml 10% Na‐deoxy-
cholate, 1 ml 10% sodium dodecyl sulphate, pH set to
7.5, adjusted to 100 ml with H2O) for 30 min before
centrifugation and supernatant collection. 100 μg of total
protein (determined via Bradford assay) was then used
for sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE). Following electrophoresis, pro-
teins were transferred to PVDF membranes which were
Gibbons et al. BMC Cancer  (2015) 15:425 Page 4 of 16subsequently blocked in 1% skim milk powder made up
in Tris buffered saline (TBS, 2.42 g Tris base, 8 g NaCl,
made up to 1 L with autoclaved Milli‐Q water, pH 7.6)
for 1 h. Membranes were then incubated overnight in
appropriate primary antibodies (Survivin and Tubulin:
Santa Cruz, all other antibodies: Cell Signalling) diluted
to 1:1000 in TBS followed by 1 h in appropriate second-
ary antibodies (Sigma-Aldrich) with washes after each
incubation. Membranes were exposed to chemilumines-
cent reagents and imaged via ChemiDoc XRS camera
(BioRad). Band densities analysed via Image J (National
Institutes of Health).Statistical analysis
All statistical analysis was performed via Student’s t-test.Results
BLf induces cytotoxicity and reduces the proliferative
ability of MDA-MB-231 and MCF-7 cells
The effect of both Apo-bLf and Fe-bLf on cytotoxicity
and proliferation were evaluated in the breast cancer
cells MDA-MB-231 and MCF-7. Cells were treated with
bLf for 24 and 48 h at concentrations of 0, 5, 10, 20, 30
and 40 nM. In order to quantify cell death, Lactate de-
hydrogenase (LDH) cytotoxicity assays were employed
to determine cytotoxicity.
Apo-bLf was the most effective at inducing cell cyto-
toxicity with significant increases in cytotoxicity at con-
centrations of 20, 30 and 40 nM in MDA-MB-231
(133.05%, p = 0.003, 112.53%, p = 0.003 and 110.17%, p =
0.007, respectively) and MCF-7 cells (68.58%, p = 0.001,
90.68%, p = 0.00001 and 99.31%, p = 0.000006, respect-
ively) after 48 h (Fig. 1a). Furthermore, Apo-bLf demon-
strated significant toxicity after 24 h in MCF-7 cells at
concentrations of 20 nM (25.93%, p = 0.02), 30 nM
(40.09%, p = 0.001) and 40 nM (61.97%, p = 0.001)
(Fig. 1b). Fe-bLf demonstrated significant increases in
cytotoxicity in MDA-MB-231 cells at concentrations of
10, 20 and 30 nM (51.81%, p = 0.04, 61.76%, p = 0.01 and
42.01%, p = 0.048) after 48 h (Fig. 1a) yet no significant
cytotoxicity in MCF-7 cells (Fig. 1b).
CyQUANT® assay results indicated a reduction in pro-
liferation following treatments with both Apo-bLf and
Fe-bLf after 48 h in MDA-MB-231 cells (Fig. 1c). Apo-
bLf significantly reduced proliferation at concentrations
of 30 and 40 nM (67.30%, p = 0.01 and 54.87%, p = 0.003,
respectively) and Fe-bLf at concentrations of 20, 30 and
40 nM (74.86%, p = 0.04, 52.89%, p = 0.003 and 46.40%,
p = 0.008) after 48 h. Furthermore, Apo and Fe-bLf re-
duced proliferation after 48 h in MCF-7 cells at 40 nM
(53.93%, p = 0.03 and 51.35%, p = 0.01 respectively)
(Fig. 1d). No significant increase in proliferation was ob-
served in any treatment condition in either cell line.Morphological images (Fig. 2a and b) indicated signifi-
cant cell death after 48 h. Cells in treatment groups
showed detachment from culture surfaces, blebbing and
rounded edges. Cell fragmentation and decrease in num-
ber was also observed compared with untreated cells
over the same time period. These effects were observed
more frequently with increasing concentration in MDA-
MB-231 (Fig. 2a) and MCF-7 (Fig. 2b). These results in-
dicate a time and dose dependant effect of Apo-bLf on
MDA-MB-231 and MCF-7 cells in terms of increasing
cell cytotoxicity and decreasing cell proliferation. Fur-
thermore, these results also highlight that Fe-bLf is less
effective when compared with Apo-bLf in these breast
cancer cells.
Apo-bLf and Fe-bLf show no cytotoxic effects in MCF-10-2A
mammary epithelial cells
Both Apo-bLf and Fe-bLf were also tested in a normal,
non-tumourigenic mammary epithelial cell line MCF-
10-2A. LDH cytotoxicity assays were performed on cells
treated for 24 and 48 h at concentrations of 5, 10, 20, 30
and 40 nM. No significant increase in cytotoxicity was
observed after either 24 or 48 h with any of the Apo-bLf
and Fe-bLf treatments (Fig. 1e).
Apo-bLf and Fe-bLf efficiently internalizes into treated
cells
BLf is known to internalize into normal and cancer cells
through cell surface (membrane) receptor mediated endo-
cytosis [10, 30, 41, 42]. In order to determine the level
of internalisation and localisation of bLf within breast
cancer cells, we performed immunofluorescence. Cells
were treated with either Apo-bLf or Fe-bLf at 40 nM
for 4 h. A reduced time period was used to reduce cell
death so that cells could still be visualised by confocal
microscopy. Both forms of bLf internalised into MDA-
MB-231 (Fig. 2c) cells with fragmentation displayed in
cells treated with Fe‐bLf at 40 nM. Both forms of bLf
were localised in the membrane, cytoplasm and nucleus
of the cells. Untreated MCF-7 cells displayed healthy,
cluster formation (Fig. 2d). After treatment with both
Apo-bLf and Fe-bLf, internalisation of bLf into the mem-
brane, cytoplasm and nucleus was observed (Fig. 2d). It is
apparent that Apo-bLf induces mass cell fragmentation
(Fig. 2d) which is due to the high cytotoxic potential of
Apo-bLf. Cell clusters were also much smaller in treated
cells compared with untreated cells, indicating the effect
of treatment on cell viability following bLf internalisation.
Apo-bLf and Fe-bLf treatments decrease the migration
and invasion potential of breast cancer cells
As migration and invasion are key properties of cancer
cells leading to metastases and secondary tumour sites
within the body, assays were performed to determine the
Fig. 1 Cytotoxicity and proliferation in MDA-MB-231, MCF-7 and MCF-10-2A cells following Apo-bLf and Fe-bLf treatments. Lactate dehydrogenase
assay (LDH) results demonstrating cytotoxicity in cells after 24 and 48 h Apo and Fe-bLf treatments in MDA-MB-231 (a), MCF-7 (b) and MCF-10-2A cells
(e). CyQUANT® assay results represent cell proliferation levels after 24 and 48 h Apo and Fe-bLf treatments in MDA-MB-231 (c) and MCF-7 cells
(d) including high (20% FBS) and low (untreated) controls. Data represented as mean with + SEM (n = 6). * = p < 0.05 compared with untreated (0 nM)
group, ** = p < 0.01 compared with untreated (0 nM). Statistical analysis performed using Student’s t-test
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assays indicated a significant reduction in the capacity
of MDA-MB-231 and MCF-7 (Fig. 3a) cells to migrate
through a porous membrane after treatment for 24 h
with each Apo-bLf and Fe-bLf at concentrations of 5
and 10 nM. The greatest reduction in migration was
observed with 10 nM Apo-bLf with 26.45% (p = 0.001)
of MDA-MB-231 and 38.78% (p = 0.001) of MCF-7 cells
migrating. Invasion assays (Fig. 3b and c) were per-
formed with ECM. The same trend was observed in
MDA-MB-231 cells with 29.85% (p = 0.001) of cells in-
vading after treatment with 10 nM Apo-bLf. MCF-7showed a large reduction with 10 nM Apo-bLf (50.00%,
p = 0.003) however the greatest reduction in invasion
was with 10 nM Fe-bLf treatments with 26.25% (p =
0.00008) invasion.
Both bLf forms induce significant apoptosis at a different
rates in MDA-MB-231 and MCF-7 cells
In order to determine if cell death was caused by apop-
tosis, Annexin-V-Fluos labelling was performed on each
MDA-MB-231 and MCF-7 cells (Fig. 4). Cell were treated
with Apo-bLf or Fe-bLf at 20 and 40 nM for 24 h. Label-
ling was detected via Flow cytometry and gating was
Fig. 2 Cell morphology and internalization of bLf in MDA-MB-231 and MCF-7 cells. a MDA-MB-231 cells after 48 h treatments with both Apo-bLf
and Fe-bLf at concentrations of 20, 30 and 40 nM as well as untreated cells. b MCF-7 cells after 48 h treatments with both Apo-bLf and Fe-bLf at
concentrations of 20, 30 and 40 nM as well as untreated cells. All images at 400X magnification. Confocal microscope images displaying internalisation
of 40 nM Apo-bLf and Fe-bLf in both MDA-MB-231 (c) and MCF-7 (d) cells after 4 h. Arrows indicate regions on the membrane, cytoplasm and nucleus
where bLf has internalised. Cells stained with DAPI nuclear stain (blue) and immunolabelled with anti-bovine lactoferrin antibody followed by
Alexa-Fluor TRITC conjugated secondary antibody (red). Scale bars indicate 25 μm
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(Annexin-V and Propidium Iodide). Results indicated in-
creases in apoptotic cell death in MDA-MB-231 cells
treated with bLf with significant increased total apoptosis
in cells treated with Apo-bLf at 40 nM (23.30%, p = 0.03)
(Fig. 4a). Results from MCF-7 cells showed increased
apoptosis in all treatment groups with significant apop-
tosis observed in cells treated with 40 nM Apo-bLf
(46.85%, p = 0.05) and Fe-bLf at 20 nM (53.60% p = 0.02)
and 40 nM (65.15%, p = 0.04) (Fig. 4b). Furthermore, de-
creased viable cells were observed in MDA-MB-231 cells
after Apo-bLf at 40 nM and in both Fe-bLf treatment
groups and in all MCF-7 treatment groups however no
significant increase in necrotic cells was observed in
any of the treatment groups (Table 1). This indicated
that both Apo-bLf and Fe-bLf were inducing apoptosis
in each cell line.To determine the mechanism of action of apoptosis
induced by bLf, apoptotic protein arrays were performed
on each MDA-MB-231 (Fig. 5) and MCF-7 (Fig. 6) cells
following treatments with Apo-bLf and Fe-bLf for
24 h. Results indicated different mechanisms of action
between the two forms of bLf and between the cells.
MDA-MB-231 showed significant reduction in survivin
expression along with increased expression of HTRA2
with each Apo-bLf and Fe-bLf (Fig. 5b). In addition, Apo-
bLf reduced cIAP2 and SMAC was increased with Fe-bLf
(Fig. 5b). In MCF-7 cells, HTRA2 and SMAC were both
significantly increased with both forms of bLf, with a
stronger effect observed with Apo-bLf (Fig. 6b). These re-
sults indicate that bLf is having an impact on the IAP
mechanism, allowing apoptosis to progress by activating
SMAC and HTRA2 which subsequently bind IAP pro-
teins, preventing their inhibition of the caspase cascade.
Fig. 3 Effect on migration and invasion capacity of MDA-MB-231 and MCF-7 cells after treatment with bLf. Migration of MDA-MB-231 and MCF-7
(a) cells after bLf treatments for 24 h represented as a percentage of untreated (1% FBS) control migration. Invasion of MDA-MB-231 and MCF-7
cells (b) after bLf treatments for 24 h represented as a percentage of untreated (1% FBS) control invasion. * = p < 0.05 compared with 1% FBS
group. Representative images (250X magnification) of invaded cells stained with crystal violet (c)
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231 cells occurring via the intrinsic pathway with a sig-
nificant reduction in expression of anti-apoptotic pro-
teins in Bcl-2 (Apo-bLf) and PON2 (both forms of bLf)
(Fig. 5a). A reduction in extrinsic proteins FADD and
Fas (Fig. 5c) was also observed however the opposite oc-
curring in MCF-7 (Fig. 6c) with extrinsic proteins FADD
and TNF R1 each upregulated with both forms of bLf.
Furthermore, MCF-7 cell also show significant increases
of pro-apoptotic proteins Bad and cytochrome C (Fig. 6a
& d).
Cell stress proteins in MDA-MB-231 cells, HMOX1
and HSP60 were both reduced with Apo-bLf (Fig. 5e) as
were cell cycle regulators claspin, p21, p27, phospho-p53
(S15, S46 and S392) and phospho-Rad17 (S635) (Fig. 5 f).
Claspin was also significantly reduced with both Apo-bLf
and Fe-bLf (Fig. 5 f). In MCF-7 cells, cell stress proteins
were increased by both Apo-bLf and Fe-bLf including
HIF1α, HMOX2, HSP27, HSP60 and HSP70 (Fig. 6e). Fi-
nally, cell cycle regulator p21 was increased in MCF-7
cells with Apo-bLf, Claspin with Fe-bLf and phospho-p53S15 and S46 were increased with both Apo-bLf and Fe-
bLf (Fig. 6 f).
Apo-bLf and Fe-bLf forms induce increase in caspase
cleavage
Following the observations form the Apoptotic array that
bLf modulated aspects of both the intrinsic and extrinsic
pathways, as well as increases in cleaved caspase-3, the ef-
fect of bLf on cleaved initiator caspase-8 (extrinsic) and
caspase-9 (intrinsic) were assed via Western blotting. In
addition, pro and cleaved effector caspase-3 were also ana-
lysed. MDA-MB-231 and MCF-7 cells were both treated
with 40 nM Apo-bLf and Fe-bLf for 24 h. Following treat-
ments, cells were lysed with RIPA buffer and lysates were
separated via SDS-PAGE followed by Western blotting.
Identical gels were run and Western blotting performed
for GAPDH. Fold change was calculated by determining
band densities via ImageJ software, normalizing proteins
with GAPDH and calculating fold change relative to un-
treated cells.
Fig. 4 BLf-induced apoptosis in MDA-MB-231 and MCF-7 cells. Annexin-V-Fluos staining detected apoptosis in MDA-MB-231 and MCF-7 cells
following bLf treatments. Cells were treated for 24 h with Apo-bLf and Fe-bLf at concentrations of 20 nM and 40 nM. a Total apoptotic
MDA-MB-231 and b MCF-7 cells following bLf treatments. Flow cytometry plots of MDA-MB-231 and MCF-7 cells (c). Q1: Necrotic cells,
Q2: Late apoptotic/Dead cells, Q3: Viable cells, Q4: Early apoptotic cells. Total apoptotic cells were the sum of early and late apoptotic
cell populations. Data represented as means +SEM, student t-test used for statistical analysis
Table 1 Annexin-V results following bLf treatments in breast cancer cells
Early Apoptotic Cells Late Apoptotic Cells Viable Cells Necrotic Cells
MDA-MB-231 Untreated 1.75 ± 1.15 2.50 ± 2.10 94.85 ± 3.25 0.85 ± 0.05
Apo-bLf 20 nM 1.90 ± 0.60 1.10 ± 0.40 96.2 ± 1.40 0.85 ± 0.35
Apo-bLf 40 nM 5.55 ± 0.65 17.75 ± 0.05* 75.4 ± 0.10* 1.10 ± 0.5
Fe-bLf 20 nM 1.90 ± 0.30 9.30 ± 3.30 87.7 ± 3.40 1.10 ± 0.20
Fe-bLf 40 nM 3.75 ± 1.95 19.35 ± 6.85 74.00 ± 8.80 2.90 ± 0.00
MCF-7 Untreated 3.40 ± 3.20 5.25 ± 3.25 88.60 ± 7.30 2.70 ± 0.90
Apo-bLf 20 nM 2.50 ± 0.40 22.85 ± 9.65 64.95 ± 3.85 9.75 ± 6.15
Apo-bLf 40 nM 6.15 ± 0.55 40.7 ± 7.30* 51.00 ± 6.70* 2.20 ± 0.00
Fe-bLf 20 nM 12.30 ± 0.30 41.3 ± 1.40* 45.45 ± 1.65* 0.95 ± 0.05
Fe-bLf 40 nM 21.65 ± 1.65* 43.5 ± 12.10 34.15 ± 10.05* 0.70 ± 0.40
Annexin-V-Fluos staining results determined via Flow cytometry. Total populations acquired were plotted in terms of both single and dual fluorophores. Dual
channel plots were divided in to quadrants: Q1: Necrotic cells, Q2: Late apoptotic/Dead cells, Q3: Viable cells, Q4: Early apoptotic cells. Single channel plots were
used to determine total numbers of cells labelled with Annexin-V or propidium iodide. Table 1 shows average values for individual gating of both dual and single
channel plots + SEM. Statistical analysis was performed via Student’s t-test
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Fig. 5 Apoptosis protein array MDA-MB-231 breast cancer cells. Apoptosis protein array results following incubation of MDA-MB-231 cell lysate
after treatments with Apo-bLf and Fe-bLf at 40 nM for 24 h. Cell lysate (250 μg) incubated with nitrocellulose membrane pre-labelled with capture
antibodies (duplicate spots) and detected via chemiluminescence. a Bcl-2 family proteins Bad, Bax, Bcl-2 and Bcl-xL. b Inhibitor of apoptosis (IAP)
proteins cIAP-1 and 2, Livin, Survivin and XIAP, and inhibitors SMAC and HTRA2. c Extrinsic pathway proteins and receptors TRAIL 1 and 2, FADD,
Fas and TNF R1. d Pro-apoptotic proteins Pro-caspase-3, Cleaved Caspase-3 and Cytochrome C, anti-apoptotic proteins Catalase, PON2 and Clusterin.
e Cell stress proteins HIF-1α, HMOX1, HMOX2, HSP27, HSP60 and HSP70. f Claspin, p21, p27, phospho-p53 (S15), phospho-p53 (S46), phospho-p53
(S392) and phospho-Rap17 (S635). Average density determined using ImageJ software and fold change calculated compared with untreated.
Data represented as means with + SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared with the untreated group. Statistical analysis was
performed via Student’s t-test
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Apo-bLf in MDA-MB-231 cells (Fig. 7a). Fe-bLf however
did not show increases in either cleaved caspase-8 or −9.
Apo-bLf increased the active fragment (18 kDa) of cleaved
caspase-8 by 2.3 fold compared with untreated cells. Most
notably however, cleaved caspase-9 was increased by 8.9
fold with Apo-bLf.In MCF-7 cells, both cleaved caspases-8 and −9 were
increased with 40 nM Apo-bLf and Fe-bLf (Fig. 7b). The
effects of Apo-bLf and Fe-bLf were similar in their ef-
fects on cleaved caspases-8 and −9. Active caspase-8
(18 kDa fragment) was increased to 1.5 and 1.3 fold with
Apo-bLf and Fe-bLf respectively while the remaining,
unused fragments (41 and 43 kDa) from the pro-caspase
Fig. 6 Apoptosis protein array MCF-7 breast cancer cells. Apoptosis protein array results following incubation of MCF-7 cell lysate after treatments
with Apo-bLf and Fe-bLf at 40 nM for 24 h. Cell lysate (250 μg) incubated with nitrocellulose membrane pre-labelled with capture antibodies
(duplicate spots) and detected via chemiluminescence. a Bcl-2 family proteins Bad, Bax, Bcl-2 and Bcl-xL. b Inhibitor of apoptosis (IAP) proteins
cIAP-1 and 2, Livin, Survivin and XIAP, and inhibitors SMAC and HTRA2. c Extrinsic pathway proteins and receptors TRAIL 1 and 2, FADD, Fas and
TNF R1. d Pro-apoptotic proteins Pro-caspase-3, Cleaved Caspase-3 and Cytochrome C, anti-apoptotic proteins Catalase, PON2 and Clusterin. e Cell
stress proteins HIF-1α, HMOX1, HMOX2, HSP27, HSP60 and HSP70. f Claspin, p21, p27, phospho-p53 (S15), phospho-p53 (S46), phospho-p53 (S392) and
phospho-Rap17 (S635). Average density determined using ImageJ software and fold change calculated compared with untreated. Data represented as
means with + SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared with untreated group. Statistical analysis was performed via Student’s t-test
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large levels of cleavage. Furthermore, cleaved caspase-9
was increased by 2.6 and 2.5 fold with Apo-bLf and Fe-
bLf respectively. Analysis of effector caspase-3 was then
performed in MDA-MB-231 (Fig. 7c) and MCF-7 (Fig. 7d)
cells. In MDA-MB-231 cells, a large decrease in pro-
caspase-3 was observed with both Apo-bLf and Fe-bLf
with expression reduced to 0.3 and 0.4 fold respectively ofuntreated cells. This was taken to indicate caspase cleav-
age and this was further confirmed by Western blot ana-
lysis of cleaved caspase-3 levels in MDA-MB-231 cells.
Cleaved caspase-3 levels increased by 2.1 fold in cells
treated with Apo-bLf and slight increase by 1.3 fold in
cells treated with Fe-bLf. In MCF-7 cells, pro-caspase-3
increased with both Apo-bLf (2.1 fold) and Fe-bLf (2.2
fold). Cleaved caspase-3 was relatively unchanged in Fe-
Fig. 7 BLf induces caspases-3, −8 and −9 cleavage in breast cancer cell lines. Western blot analysis of cleaved caspases-8 and −9 in MDA-MB-231
(a) and MCF-7 (b) cells following treatment with 40 nM Apo-bLf and Fe-bLf for 24 h. Western blot analysis of pro and cleaved caspase-3 in MDA-MB-231
(c) and MCF-7 (d) cells following treatment with 40 nM Apo-bLf and Fe-bLf for 24 h. Lysates were collected and 100 μg loaded and run on standard
SDS-PAGE followed by transfer to PVDF membranes. Membranes were then blocked with 1% skim milk followed by incubation with anti-cleaved
caspases-3, −8 and −9 primary antibodies (Cell Signalling) and anti-mouse secondary antibody (Sigma-Aldrich). Membranes were viewed via
XRS camera. Band densities determined by ImageJ software and compared with untreated (0 nM). Separate, identical gels were run for GAPDH
(Santa Cruz) which were used to normalize band densities. Band density analysis was performed using ImageJ software. Fold change was calculated
relative to untreated cells. Relative fold change values per band are indicated below blots as well as plotted on graphs
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(Fig. 7d).
BLf treatment leads to time and dose dependent
down-regulation of survivin protein expression in both
MDA-MB-231 and MCF-7 cells
As survivin is a key IAP protein in cancer and significant
reduction was observed in MDA-MB-231 cells in apop-
totic arrays following 24 h treatments (Fig. 5b), Western
blotting was performed on a greater concentration range
for 48 h in each cell line. Cells were treated with Apo-
bLf and Fe-bLf at 20, 30 and 40 nM and cell lysates were
blotted for survivin. Survivin was detected in both un-
treated lysates (Fig. 8). Survivin was greatly reduced in
all treatment groups with reduction in MDA-MB-231
cells to 0.4 and 0.1 fold with 20 nM Apo-bLf and Fe-bLf
respectively. Survivin expression in MCF-7 cells was re-
duced to 0. 5 and 0.3 fold with 20 nM Apo-bLf and Fe-
bLf and to 0.1 fold that of untreated cells with 30 nM
Apo-bLf. No survivin was detected in MDA-MB-231
cells with either form of bLf at concentrations of 30 and40 nM. Survivin was also not detected in MCF-7 cells
after treatment with Fe-bLf at 30 nM and both forms at
40 nM. Western blotting confirmed findings from the
apoptotic array and provided important evidence for the
mechanism of bLf in terms of its apoptosis-inducing
potential.
Discussion
The presence of cell fragmentation (apoptotic bodies) in
the images taken of cells after treatment indicates the
strong cytotoxic effects of bLf in breast cancer cells. In-
creased growth inhibition and apoptosis have been dem-
onstrated in native bLf treated colon, lung and squamous
cancer cells in vivo [18, 19]. Furthermore, our findings in
2008 demonstrated that mice fed with Fe-bLf showed
greater reduction in Lewis lung carcinoma, B16 melanoma
and EL4 lymphoma tumour size than identical mice fed
with natural bLf or Apo-bLf [24]. Interestingly, in the
present study, both human breast carcinoma derived can-
cer cells showed increased cytotoxicity with Apo-bLf com-
pared with Fe-bLf particularly after 48 h. This enhanced
Fig. 8 BLf reduces survivin expression in breast cancer cell lines. Western blotting for survivin of MDA-MB-231 and MCF-7 cell lysates following
treatments for 48 h with Apo and Fe-bLf at 20, 30 and 40 nM. Lysates were collected and 100 μg loaded and run on standard SDS-PAGE followed
by transfer to PVDF membranes. Membranes were then blocked with 1% skim milk followed by incubation with anti-survivin primary antibody
(Santa Cruz) and anti-mouse secondary antibody (Sigma-Aldrich). Membranes were viewed via XRS camera. Band densities determined by ImageJ
software and compared with untreated (0 nM). Separate, identical gels were run for Tubulin which were used to normalize band densities. Band
densities determined by ImageJ software and compared with untreated (0 nM). Separate, identical gels were run for Tubulin (Santa Cruz) which
were used to normalize band densities. Band density analysis was performed using ImageJ software. Fold change was calculated relative to
untreated cells. Relative fold change values per band are indicated below blots as well as plotted on graphs
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or cell line specific, and could possibly be related to iron
metabolism in breast cancer cells with Apo-bLf playing a
role in chelation and iron sequestering. Fe-bLf however
was able to induce higher levels of apoptosis in MCF-7
cells in Annexin-V assays. It is also noteworthy to mention
that native bLf has been reported to induce apoptosis and
inhibit proliferation in T47D and HS578D breast cancer
cell lines [21] however concentrations used were much
higher (0.125-125 μM, compared with 5–40 nM in this
study). While it is possible that the difference in dosage
levels is cell specific, through published [10, 25] and un-
published work in our laboratory, we believe this isn’t the
case. We have observed similar cytotoxicity, growth inhib-
ition and apoptosis effects of bLf forms at the nanomolar
concentration range, over a range of cell lines obtained
from human carcinomas of different origin such as colon
(SW480 and Caco-2), liver (Hep3B) and melanoma (SK-
MEL-2 and SK-MEL-28). Moreover, The study in in T47D
and HS578D breast cancer cell lines [21], was performed
with native bLf (15-20% Fe3+ saturated), thus the dosage
level difference could be due to the modification of iron
saturation levels of bLf given that the work we have per-
formed is with Apo-bLf (iron free) and Fe-bLf (ironsaturated). As it is vital to keep dose levels as low as pos-
sible, it is encouraging that modification of bLf in terms of
iron saturation can allow such reduced dosage levels to be
achieved. Moreover, due to its gut-enzyme resistant nature
leading to increased bioavailability at tumour sites follow-
ing oral administration [25], Fe-bLf has a better translation
potential as a therapeutic. Encouragingly, no cytotoxicity
was detected in normal mammary epithelial cells, MCF-
10-2A even after 48 h with either form of bLf tested. This
is an important finding given the systemic toxicity often
associated with traditional chemotherapeutic agents.
Invasion and migration assays indicated that both forms
of bLf have the capacity to reduce these metastatic proper-
ties of both MDA-MB-231 and MCF-7 cells. Previously,
native bLf has been shown to inhibit migration in breast
cancer cells via scratch test assays [21]. We report here
however that iron free and >90% iron saturated bLf each
have the capacity to reduce both migration and invasion
in both MDA-MB-231 and MCF-7 cells. It is also prudent
to note that Apo-bLf and Fe-bLf were used at concentra-
tion of 5 and 10 nM compared with 12.5 μM of native bLf
in previous studies. In addition, it was observed that cells
in untreated groups were able to fully pass through the
pores whereas treated cells showed limited movement and
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possibly indicates that more time would be required for
them to translocate and that bLf can reduce their move-
ment capacity. This is an important and novel finding as
migration and particularly invasion are key factors of can-
cer cells allowing them to travel through the body and cre-
ate secondary cancer sites.
The ability of cancer cells to systematically avoid apop-
totic mechanisms and signals is directly linked to their un-
controlled growth and proliferation subsequently allowing
invasion and metastasis throughout the body [43]. We re-
port here that both Apo-bLf and Fe-bLf significantly in-
duce apoptosis in MDA-MB-231 and MCF-7 cells in a
dose dependent manner. Apoptosis induced by bLf has
been reported in several instances via both the extrinsic
and intrinsic pathways [7, 20, 22, 23, 44]. Furthermore
apoptosis was reported in two human breast cancer cell
lines (different to the two cancer cell lines used in the
present study) following native bLf treatment [21]. BLf
has been shown to up-regulate the sensitivity of extrin-
sic pathway death receptor Fas in the colon mucosa of
azoxymethane-induced colon tumour bearing rats [22]
as well as up-regulation of the active forms of both
caspase-3 and −8 after treatments with bLf [23]. In
addition, studies have also reported that bLf reduces
the levels of intrinsic protein Bcl-2 in stomach cancer
cells [20] as well as caspase-3 cleavage in squamous cell
carcinoma [44]. In line with these findings, we report
here that in MDA-MB-231 cells, Bcl-2 expression is re-
duced with Apo-bLf as is Pro-caspase-3, indicating possible
cleavage (Fig 5a & d) which was confirmed via Western
blotting (Fig 7c).
Lactoferricin, a peptide derived from lactoferrin has also
demonstrated increased apoptosis via the intrinsic path-
way in leukemic and breast carcinoma cells by activating
caspases-3 and -9 but not caspase-8 [45, 46]. However, it
was since shown that lactoferricin induces apoptosis in
B-lymphoma in a caspase-independent fashion [47] and
shown to induce apoptosis and activate caspases-3, −7,
−8 and −9 in gastric cancer thus implying that lactofer-
ricins activity may be tissue/cell specific [48]. This ap-
pears to be possible in the case of the current study as
MDA-MB-231 and MCF-7 appear to have distinct dif-
ferences in the apoptotic factors activated following in-
cubation with Apo-bLf and Fe-bLf.
It is apparent that bLf-induced apoptosis is higher in
MCF-7 cells as observed through Annexin-V and by the
levels of apoptotic molecule modulation determined via
apoptotic array including cell stress proteins and cell
cycle regulators. It may be possible that higher concen-
trations of bLf may induce similar level of apoptosis in
MDA-MB-231 cells. A possible cause for this difference
in behaviour may be due to the p53 status in the cell
lines. MDA-MB-231 cells and MCF-7 cells differ in theirp53 status with MDA-MB-231 cells harbouring a p53
mutation while MCF-7 are wild type. Differences in p53
modulation were observed in the apoptotic array with
increases in phospho-p53 at serine 15 and 46 was ob-
served with both Apo-bLf and Fe-bLf in MCF-7 cells
while this was not observed in MDA-MB-231 cells. In
fact, the opposite was observed in MDA-B-231 cells with
all three p53 phosphorylation sites studies being down-
regulated following both Apo-bLf and Fe-bLf treatments.
Given the complexity and importance of the p53 mechan-
ism, extensive investigation into this finding could prove
very interesting.
Survivin is a major inhibitor of apoptosis protein (IAP)
acting in part by blocking the effect of caspases-3, −7
and −9 to allow cell evasion of apoptosis [1–3]. The role
of native bLf, and its forms containing different levels of
iron in targeting survivin expression in cancer cells is yet
to be fully elucidated. More recently, we have reported
that native bLf downregulates survivin gene expression
in SW480 colon cancer cells [7], and Fe-bLf nanoformu-
lation targets survivin to kill colon cancer stem cells [41]
Here however it was found that MDA-MB-231 cells
showed highly significant decreases in survivin protein
expression levels, as well as strong increases in IAP in-
hibitors SMAC/DIABLO and HTRA2. SMAC/DIABLO
was increased with Fe-bLf and HTRA2 was increased
with both Apo-bLf and Fe-bLf. Furthermore, SMAC and
HTRA2 were also upregulated in MCF-7 cells with both
Apo-bLf and Fe-bLf. Both SMAC and HTRA2 inhibit
IAPs by binding to them allowing caspase activation dur-
ing apoptosis [49]. Western blot analysis of initiator
caspases-8 and −9 as well as effector caspase-3 in MDA-
MB-231 cells revealed large increases in cleavage of all
three caspases, predominantly with Apo-bLf. This was in
line with apoptosis levels determined via Annexin-V Fluos
staining. The largest increase in caspase cleavage in MDA-
MB-231 cells was with Apo-bLf in caspase-9 with an
increase greater than 8-fold. This is consistent with the re-
duction in survivin given that survivin is known to bind
and inhibit caspase-9 cleavage [50, 51]. Thus, apoptosis in
MDA-MB-231 cells appears predominately through the
modulation and suppression of IAPs, and increased activ-
ity of IAP inhibitors (Fig 9). It was also observed that
cleaved caspases-8 and −9 were increased in MCF-7 cells
following both Apo-bLf and Fe-bLf indicating that the in-
creases observed in the IAP inhibitors could be contribut-
ing to the activation of these caspases.
Survivin expression was significantly reduced by bLf
treatments at the protein level in both cell lines. Most
notably, this is the first report of bLf reducing survivin
in breast cancer cells and confirms our earlier findings
in colon cancer cells. Both Apo-bLf and Fe-bLf have the
capacity to reduce survivin protein expression demon-
strated via Western blotting and protein array. Survivin
Fig. 9 (See legend on next page.)
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Fig. 9 Apoptotic mechanisms in MDA-MB-231 and MCF-7 cells following treatment with Apo-bLf and Fe-bLf. BLf is internalized by membrane
bound receptors such as Lf receptors via receptor mediated endocytosis. Once internalized, bLf modulates various apoptotic molecules as indicated by
the red arrows. This modulation is cell specific as well as bLf form specific as some molecules are only activated or inhibited by one form of bLf
Gibbons et al. BMC Cancer  (2015) 15:425 Page 15 of 16downregulation was shown after 48 h in both cancer cell
lines (Fig. 8) and after 24 h in MDA-MB-231 cells (Fig 5b).
As compared to normal cells, survivin is overexpressed in
almost all cancer types and considered a validated target
for anti-cancer therapies [52], thus bLf shows great poten-
tial for this role. It is important to note that despite a
number of survivin inhibitors being tested in clinical trials,
none have passed this phase due to their toxicity issues
where bLf has a proven safety profile [25, 30, 41].
Future investigations into the efficacy of Apo-bLf and
Fe-bLf in in vivo models are of vital importance. Ideally,
oral delivery is the preferred administration route due to
the relative ease and patient compliance. Clinical trials in
patients with colorectal polyps revealed a preventative po-
tential of native bLf delivered daily (3.0 g) for 12 months
[53, 54]. Furthermore, native bLf delivered in mouse and
rat diet in cancer treatment models revealed reduction in
tumour sizes in colon, esophageal, lung and [24, 55]. In
addition, orally delivered Fe-bLf has been shown to aug-
ment the effects of traditional chemotherapeutics in breast
and colon cancer models [24, 27]. These studies indicate
that orally delivered bLf is a therapeutically viable delivery
route. To further enhance the absorption and delivery of
bLf, we have also reported the successful inhibition of
xenograft tumours via oral delivery of nanoformulated
bLf. Ceramic core, Fe-bLf encapsulated nanoparticles
coated with chitosan and alginate were developed and de-
livered to mice bearing Caco-2 (colon cancer) xenograft
tumours [25]. Tumour retardation was observed with suc-
cessful delivery of Fe-bLf to the tumour site indicating that
oral delivery of nanoformulated bLf may be a successful
strategy to enhance absorption in the gut. Moreover,
nanoformulated Fe-bLf was found to be highly signifi-
cantly effective when given orally, as a pretreatment. This
strategy could be applied to other cancers including breast
cancer.
Conclusions
In conclusion, it is reported that while both Apo-bLf
and Fe-bLf showed anti-tumourigenic properties, Apo-
bLf demonstrated an enhanced effect over Fe-bLf at in-
ducing cytotoxicity and reducing invasion and migration
in both cancer cell lines while Fe-bLf was more effective
at inducing apoptosis in MCF-7 cell lines. This is a par-
ticularly novel finding given that iron saturated bLf has
been found to be more efficient in colon cancer models
in previous studies. Given that no significant cytotoxicity
was detected in normal MCF-10-2A cells our findings
highlight that bLf has great potential as a safe anti-cancer agent with cell-type specific effects. Furthermore,
the modulation of different apoptotic molecules between
MDA-MB-231 and MCF-7 cell highlights a multifunc-
tional role of bLf in breast cancer cells. While it is evi-
dent that bLf ultimately induces caspase cleavage and
finally apoptosis in both cancer cell lines, it is apparent
that different pathways are being activated in the
process, namely the IAP pathway in MDA-MB-231 cells
and the p53 pathway in MCF-7 cells (Fig. 9).
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